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Abstract 22 
Resistance to ß-lactams is constantly increasing, due to the emergence of totally new 23 
enzymes, but also to the evolution of pre-existing ß-lactamases. GES-1 is a clinically-24 
relevant extended-spectrum E-lactamase (ESBL) hydrolyzing penicillins and broad-25 
spectrum cephalosporins, but sparing monobactams and carbapenems. However, 26 
several GES-1 variants (i.e. GES-2 and GES-5) previously identified among clinical 27 
isolates display an extended spectrum of activity toward carbapenems. To study the 28 
evolution potential of the GES-1 E-lactamase, this enzyme was submitted to in-vitro 29 
directed evolution, with selection on increasing concentrations of the cephalosporin 30 
cefotaxime, the monobactam aztreonam, or the carbapenem imipenem. The highest 31 
resistance levels were conferred by the combination of up to four substitutions. The 32 
A6T, E104K, G243A variant selected on cefotaxime, and the A6T, E104K, T237A, 33 
G243A variant selected on aztreonam, conferred high resistance to cefotaxime, 34 
ceftazidime, and aztreonam. Conversely, the A6T, G170S variant selected on imipenem 35 
conferred high resistance to imipenem and cefoxitin. Noteworthy, the A6T substitution 36 
involved in higher MICs for all ß-lactams is located in the leader peptide of the GES 37 
enzyme, therefore not present in the mature protein. Acquired cross resistance was not 38 
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observed since selection with CTX or ATM did not select for resistance to IPM and vice 39 
versa. Here we demonstrated that E-lactamase GES-1 exhibits peculiar properties with a 40 
significant potential to gain activity toward broad-spectrum cephalosporins, 41 
monobactams, and carbapenems. 42 
43 
44 
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INTRODUCTION45 
The main mechanism of resistance to ß-lactams in Gram negatives is the production of ß-46 
lactamases, which are classified into four molecular classes, namely A, B, C, and D based on 47 
protein sequence analysis (1). Enzymes belonging to class A, C, and D, are serine enzymes, 48 
while those belonging to class B are metallo-enzymes requiring zinc ions for activity (2, 3). 49 
Over the past 70 years, since the introduction of penicillins and cephalosporins, the massive 50 
use of broad-spectrum ß-lactams has been at the origin of the selection of ß-lactamases with 51 
broadened hydrolytic activities. Emergence of those broad-spectrum ß-lactamases may 52 
correspond to three main phenomena; i) the evolution of pre-existing narrow-spectrum ß-53 
lactamases with an extension of their hydrolytic profile due to key amino-acid substitutions, 54 
as observed for TEM and SHV E-lactamases, ii) the acquisition of enzymes possessing an 55 
intrinsic broad-spectrum hydrolytic activity, as observed for all CTX-M-type extended-56 
spectrum E-lactamases (ESBLs) (4, 5), and iii) the evolution of broad-spectrum enzymes to 57 
expand or increase their hydrolytic activity to carbapenems. 58 
GES-1 is an ESBL firstly identified in a Klebsiella pneumoniae (6), and then extensively 59 
reported from clinical isolates in Pseudomonas aeruginosa and Acinetobacter baumannii (7-60 
10), but also frequently from the environmental (11-13). Similarly to other ESBLs, GES-1 61 
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hydrolyses penicillins and broad-spectrum cephalosporins, spares carbapenems, and is 62 
susceptible to the activity of clavulanic acid as inhibitor. However, by contrast to most 63 
ESBLs, GES-1 has a low activity toward the broad-spectrum cephalosporin cefotaxime 64 
(CTX), and does not hydrolyze monobactams (6). The GES family comprises 24 variants 65 
(GES-1 to GES-24) identified from clinical isolates, some of them having amino acid 66 
substitutions conferring peculiar hydrolytic properties (Table 1). The G170N and G170S 67 
substitutions (Ambler numbering [1]), located in the omega-loop of the enzyme and first 68 
described in GES-2 and GES-5, confer extended activity against carbapenems and cefoxitin 69 
(FOX) (this latter only for G170S), decreased hydrolysis of broad-spectrum cephalosporins, 70 
and decreased susceptibility to ß-lactam inhibitors (Table 1) (9, 14-16). On the other hand, the 71 
E104K, G243A, and G243S substitutions, identified in several GES variants, have been 72 
shown to confer higher activity toward broad-spectrum cephalosporins and the monobactam 73 
aztreonam (ATM), together with an increased susceptibility to ß-lactam inhibitors (Table 1).  74 
Given its ability to evolve, GES-1 was chosen as a model enzyme for testing the 75 
diversification potential of ESBLs. Therefore, the GES-1 enzyme was subjected to directed 76 
evolution; this method consists of iterative rounds of random mutagenesis and selection, and 77 
is commonly used for altering or optimizing protein function (17, 18). GES-1 was submitted 78 
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to three different ß-lactam-based selective pressures, namely the broad-spectrum 79 
cephalosporin CTX, ATM, or the carbapenem imipenem (IPM). A series of variants with 80 
increased and/or broadened specificity was selected, from which the causality between the 81 
increased hydrolytic activity and the mutations could be inferred, and future evolutionary 82 
trajectories predicted. 83 
 84 
MATERIALS AND METHODS85 
Construction and selection of mutagenized GES-1 libraries. The pBSKSII-kanR-86 
GES-1 plasmid was used as the reference plasmid coding for GES-1. Plasmid pBSKSII-kanR 87 
is derived from pBluescriptII (a high copy number plasmid, 500 copies per cell), and encodes 88 
resistance to kanamycin. The entire blaGES-1 coding region (6) was amplified, the amplicon 89 
including 31 bp upstream of the ATG start, with primers No50 (GES-1-HindIII-F, 5'-90 
gatgatAAGCTTACAAAGATAATTTCCATCTCAAGG-¶ DQG 1R *(6-1-NotI-R, 5'-91 
gatgatGCGGCCGCCTATTTGTCCGTGCTCAGGATG-¶DQGcloned into the HindIII/NotI 92 
restriction sites of pBSKSII-kanR. The construct was verified by sequencing. Random 93 
mutagenesis was performed with the GenMorph II Random Mutagenesis Kit (Agilent 94 
Technologies, Santa Clara, CA), with primers No50 and No51, following the manufacturer 95 
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recommendations. The PCR amplified mutagenized product was purified, digested, and 96 
ligated into the HindIII/NotI restricion sites of pBSKSII-kanR. After purification, the ligation 97 
mixture was transformed into TOP10 electro-competent E. coli cells (Life Technologies, Zug, 98 
Switzerland). The library was plated on Luria broth plates supplemented with 25 g/ml of 99 
kanamycin. At each round, the complexity of the library was at least 105 independent clones. 100 
The mean substitution rate was of 2 nucleotides per molecule, based on sequencing of 10 101 
clones. This corresponds to at least 6x104 distinct sequences, as calculated with the library 102 
statistics program PEDEL (19). For selection, the libraries were plated on increasing doses of 103 
the indicated antibiotic, with a 2-fold increment. Plasmids recovered from the clones obtained 104 
with the highest antibiotic concentrations (usually 100 to 300 clones) were isolated, re-105 
transformed, and plated again on the same antibiotic concentration. At this step, at least 4 106 
clones were analyzed by sequencing, and the rest of the clones was isolated as a pool, and 107 
used as a basis for the next round of random mutagenesis. Constructs with different 108 
combinations of mutations were made by sub-cloning, or with the Q5 Site-Directed 109 
Mutagenesis Kit (New England BioLabs, Ipswich, MA).  110 
MICs, specific hydrolytic activities, and IC50s measurements. MICs were measured 111 
by Etest (bioMérieux, Marcy l'Etoile, France). Specific hydrolytic activities were measured 112 
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from whole cell extracts of recombinant E. coli strains producing the different GES variants 113 
as described (6). Assays were performed in 500 l total volume, using 150 M (for 114 
benzylpenicillin [PEN], ATM, IPM, FOX) or 75 PM (for CTX and ceftazidime [CAZ]) of 115 
substrate. Hydrolysis measurements were performed at room temperature with a JENWAY 116 
spectrophotometer (Staffordshire, UK). The protein concentrations were measured with 117 
Bradford Reagent (Sigma-Aldrich, Buchs, Switzerland). The results were expressed in nmoles 118 
x min-1 x Pg-1 extract. Experiments were made in triplicates from 3 independent cultures. 119 
Inhibitory concentrations inhibiting 50% of the hydrolysis activity (IC50) were measured for 120 
clavulanic acid using PEN as substrate. A 3-min long preincubation step with clavulanic acid 121 
was used before adding PEN. Those experiments were performed in triplicates with three 122 
independent cultures. 123 
 124 
RESULTS 125 
Selection of GES variants conferring increased resistance to CTX, ATM, and 126 
IPM by directed evolution. GES mutants conferring increased resistance to CTX, ATM, or 127 
IPM were recovered after three (for ATM and IPM) or four (for CTX) rounds of mutagenesis 128 
and selection. Over the rounds the variants were successively selected with 1, 2, 4, and 129 
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16Pg/ml of CTX, with 1, 16, 128, and 256Pg/ml of ATM, or with 0.1, 0.125, and 0.25 Pg/ml 130 
of IPM. Additional mutagenesis steps could not select variants with higher MICs. At the end 131 
of each round, at least four clones were sequenced. Mutations common to several clones were 132 
anticipated to be the phenotypically relevant ones, but additional substitutions, silent or not, 133 
did accumulate throughout the mutagenesis rounds. Therefore, some constructs were 134 
specifically generated to definitely correlate amino acid substitutions to resistance phenotypes 135 
(data not shown). The corresponding so-called cured variants (GES-C1 to -C5 for selection 136 
with CTX, GES-A1 to -A5 for selection with ATM, and GES-I1 to -I3 for selection with 137 
IPM) harboring the corresponding amino acid changes are depicted in Table 2A-C. The 138 
sequences of the originally isolated clones are listed in Table S1. 139 
MICs of ß-lactams for the selected mutants. Upon selection with CTX, the A6T 140 
substitution (clone GES-C1), located in the signal peptide, was the only mutation selected 141 
after round 1 (Table 2A). At round 2, substitutions E104K or G243S were added to A6T 142 
(clones GES-C2 and GES-C3), and GES-C4 (A6T, G243A) was selected at round 3. 143 
Combination of substitutions A6T, E104K, G243A was selected at round 4 (clone GES-C5). 144 
MICs of CTX for these constructs gradually increased during the directed evolution, from 145 
0.75 g/ml for GES-1 to 48 g/ml for GES-C5 (Table 2A). MICs of ATM and ceftazidime 146 
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(CAZ) increased concomitantly to those of CTX, while MICs of FOX, IPM, and the 147 
carbapenem ertapenem (ETP) remained unchanged (Table 2A). Four additional constructs 148 
were made to dissect the role of each amino acid change. Single E104K, G243S, or G243A 149 
substitutions (clones GES-C6, GES-C7, and GES-C8, respectively) conferred a lower 150 
resistance than A6T (clone GES-C1). Combination of E104K and G243A (clone GES-C9) 151 
was slightly more efficient than single mutations (Table 2A). Clone GES-C5 exhibiting 152 
substitutions A6T, E104K, and G243A combined three changes that individually conferred 153 
modest MIC increases, but when combined together resulted into a variant for which the MIC 154 
of CTX reached 48 g/ml.  155 
When selecting with ATM, single E104K (clone GES-A1) or G243A (clone GES-A2) 156 
mutations were selected in round 1, while a combination of those two was selected at round 2 157 
(clone GES-A3). Ultimately, clones selected on ATM-128 additionally harbored a T237A 158 
substitution (E104K, T237A, G243A, clone GES-A4), and those selected on ATM-256 159 
harbored the A6T substitution in addition to the three other changes (clone GES-A5) (Table 160 
2B). MICs of ATM for these constructs increased during the directed evolution, from 0.25 161 
g/ml for GES-1 to >256 g/ml for clones GES-A4 and GES-A5. In parallel MICs of CAZ 162 
increased sharply, while those of CTX more modestly. No change in MICs of FOX, IPM, or 163 
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ETP was observed (Table 2B). Each of the three E104K, T237A, or G243A substitutions 164 
(clones GES-C6, GES-A6, and GES-A2, respectively) had slightly increased MICs of ATM 165 
(from 1.5 to 3 g/ml). Any dual combination resulted into higher MICs of ATM (from 12 or 166 
32 g/ml, clones GES-A3, -A7 and -A8), while the triple mutant had an MIC of ATM of 167 
>256 g/ml (clone GES-A4) (Table 2B). Of note, while the T237A substitution correlated 168 
with increased MICs of ATM and CAZ, it was systematically deleterious for the MIC of 169 
CTX. 170 
When selecting with IPM, substitution G170S was selected at round 1 (clone GES-I1). Then 171 
substitution c-1t lying 1 bp before the ATG start codon (clone GES-I2) and finally 172 
substitution A6T (clone GES-I3) were selected at rounds 2 and 3 (Table 2C). Overall, MICs 173 
of IPM increased from 0.25 g/ml for wild-type GES-1 to 2 g/ml for clone GES-I3. MICs of 174 
ETP and FOX increased concomitantly but conversely, MICs of ATM, CTX, and CAZ were 175 
lowered once the G170S mutation was selected (Table 2C). 176 
In-vitro specific hydrolytic activities of the GES variants correlating with MICs 177 
values. In order to confirm that the higher MICs observed for the selected clones were indeed 178 
related to higher catalytic activities or higher amount of the different GES enzymes selected, 179 
and not to a non-enzymatic resistance mechanism, in-vitro specific hydrolytic activities of a 180 
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set of GES variants were determined. Overall, for all enzymes the increased hydrolytic 181 
activities toward CTX, CAZ, ATM, IPM, and FOX correlated with the higher MICs of the 182 
corresponding substrates (Tables 2A-C). 183 
Differential inhibition of the GES selected variants by clavulanic acid. 184 
Determination of IC50s of clavulanic acid was performed for a representative set of the GES 185 
variants. Clones GES-C1 and GES-C5 showed similar IC50 values of clavulanic acid 186 
compared to the wild-type GES-1 (Table 2A). However, clones GES-A4 and GES-A5 showed 187 
10-fold lower IC50 values (0.6 M) (Table 2B) likely due to the T237A substitution. 188 
Conversely clones GES-I3 and GES-I4 selected on IPM and harboring the G170S substitution 189 
showed significantly higher IC50 values (Table 2C). Overall, mutants selected on CTX 190 
showed similar susceptibility to clavulanic acid as GES-1, while clones selected on ATM 191 
showed increased, and clones selected on IPM lower susceptibility to clavulanic acid.  192 
193 
DISCUSSION194 
The directed evolution procedure used here combined the generation of mutagenized libraries 195 
with antibiotic selection, and allowed the selection of GES variants that may be categorized 196 
into two classes, being those selected on CTX or ATM conferring high resistance to CTX, 197 
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ATM, and CAZ on one hand, and those selected on IPM conferring high resistance to IPM 198 
and FOX on the other hand. 199 
Interestingly, the A6T substitution located into the signal sequence (18 amino-acid long for 200 
GES-1) was selected through all three evolutionary routes. Noteworthy, signal sequences are 201 
required for translocation to the periplasm (20). The A6T substitution in GES-1 systematically 202 
conferred a 3- to 8-fold increase in the MICs of CTX, ATM, and IPM (Table 2A-C). In 203 
accordance with our observation, a study including experimental mutagenesis of a consensus 204 
signal sequence fused to a ß-lactamase gene increased ampicillin tolerance level of the host 205 
cell up to 8-fold (21). To the best of our knowledge, it has never been clearly assessed that 206 
mutations in the signal sequence of any ß-lactamase may confer increased resistance to ß-207 
lactams. The impact of such substitution should therefore be further investigated as a 208 
mechanism leading to reduced susceptibility or even resistance to ß-lactams. 209 
By selecting with IPM, the G170S mutation located in the ȍ-loop of the catalytic site (amino 210 
acids 159 to 182), a highly conserved motif among the E-lactamases, was recovered. This 211 
substitution was previously shown to confer a 100-fold increased catalytic activity against 212 
IPM when compared to GES-1 (14, 22, 23). The E104 residue is exposed near the entrance to 213 
the binding site, and the E104K substitution is commonly found in the TEM family, where 214 
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this change participates to the expansion of the E-lactamase spectrum, more strikingly when 215 
associated with other substitutions such as R164S or G238S (24-26). Despite several studies, 216 
the mechanism of this synergism remains poorly understood (26). The G243A is not 217 
conserved among E-lactamases and this change might create subtle rearrangements in the 218 
disulfide bond. The T237 amino acid, together with the S70 residue, forms an oxyanion hole, 219 
which houses the ß-lactam carbonyl of the acyl-enzymes intermediate (27). Position 237, 220 
usually occupied by an Ala or Ser in most class A ß-lactamases, corresponds to a Thr residue 221 
in GES-1, but also in the PER-1 ESBL and in the class A KPC-2 carbapenemase. It was 222 
experimentally shown with KPC-2 that a T237A change resulted into lower hydrolysis of 223 
CTX (28). Conversely in TEM, the natural or experimentally generated A237T substitution 224 
confers an increased hydrolysis of CTX and a decreased hydrolysis of CAZ and ATM (22, 225 
30). These observations correlate with the detrimental effect of the T237A substitution in 226 
GES for the hydrolysis of CTX, and the beneficial effect for the hydrolysis of CAZ and ATM. 227 
Substitutions E104K, G170S, T237A, G243S, and G243A selected through our study were 228 
previously described in GES alleles identified from clinical isolates (Table 1). Noticeably, 229 
substitution G170S, increasing carbapenem hydrolysis, was previously identified in the 230 
natural carbapenemase GES-5. Substitutions E104K, T237A, and G243A were also identified 231 
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in natural GES alleles, either alone (GES-9, G243A), associated to phenotypically 232 
uncharacterized mutations (GES-3, GES-7, GES-19, GES-22), or combined with other 233 
substitutions (GES-12 and GES-17) (Table 1). As inferred from our in-vitro directed 234 
evolution experiments, GES-5, GES-12 and GES-17 may therefore be prone to evolve into 235 
more active variants. On the other hand, some GES alleles recovered from clinical isolates 236 
combined the G170S mutation conferring higher activity toward carbapenems, together with 237 
another mutation conferring increased activity toward CTX, ATM, and CAZ (see GES-6, 238 
E104K, G170S, and GES-14, G243A, G170S). Comparative studies showed that the 239 
increased hydrolysis of CTX, CAZ, or ATM mediated by E104K or G243A was abolished by 240 
the additional presence of G170S (29, 31, 32). This precludes that the natural alleles GES-6 241 
and GES-14 have been selected under successive distinct selective pressures. Similarly, 242 
detailed analysis of the CTX-M-type ESBL potential evolutionary trajectories showed that the 243 
diversification process of the CTX-M variants could only be explained by a selection with at 244 
least two antibiotics (33).  245 
Our study showed that GES enzymes can evolve into two types of variants conferring higher 246 
resistance to CTX, ATM, or to IPM. Spontaneous evolution of antibiotic resistance is a 247 
multifactorial phenomenon, given the diversity of the genetic support of resistance genes, of 248 
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the bacterial strain (including potential changes of membrane permeability or of the 249 
penicillin-binding proteins), and of the nature and the concentration of the antibiotic. As a 250 
consequence, a higher number of possible mutations and evolutionary trajectories are 251 
possible, although constrained by intramolecular interactions (34). Nevertheless, a good 252 
correlation between in-vitro prediction inferred from the analysis of the selected variants, and 253 
those found in clinical isolates has been established here. Predictions regarding the occurrence 254 
of very efficient natural variants in term of catalytic efficiency using an in-vitro directed 255 
evolution was previously demonstrated for the TEM ß-lactamase (34-37). From our study we 256 
may speculate that selection with cephalosporins or monobactam might not select for GES 257 
variants possessing carbapenemase activity, and conversely selection with the carbapenem 258 
IPM might not select for GES variants possessing increased hydrolytic activity toward CTX, 259 
CAZ, or ATM. Interestingly, as previously noticed with CTX-M-type ESBLs possessing 260 
increased activity toward broad-spectrum cephalosporins (38), some antagonistic pleiotropy 261 
was observed, such as a decreased susceptibility to ß-lactamase inhibitors of some GES 262 
variants that exhibited increased catalytic activity toward carbapenems. Overall, such an 263 
approach sheds light on how clinical alleles have been selected, and might predict the future 264 
evolutionary trajectories of the ß-lactamases according to the antibiotic selection pressure. 265 
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